Agents targeting FAP, hypoxia, GRPr, and integrins are among those that have progressed furthest in clinical trials due to their excellent avidity for tumors and pan-cancer targeting properties, and are poised to enter clinical use soon. This evidence concerns the gene FAP and cancer.